<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009670</url>
  </required_header>
  <id_info>
    <org_study_id>Inulin and SCFA production</org_study_id>
    <nct_id>NCT02009670</nct_id>
  </id_info>
  <brief_title>Inulin,SCFA Production and Metabolic Response</brief_title>
  <official_title>SCFA Production and Their Metabolic Effects After Inulin Ingestion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this placebo controlled, double-blind, randomized crossover study the investigators will
      investigate in overweight/obese healthy male volunteers whether inulin administration will
      increase intestinal SCFA production, thereby investigating whether this will lead to acute
      metabolic effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota is being increasingly recognized as an important factor in fat distribution,
      insulin sensitivity and glucose and lipid metabolism. Accordingly, the intestinal microbiota
      could play an important role in the development of obesity and type 2 diabetes mellitus. The
      role of gut-derived short-chain fatty acids (SCFA), the formation of which is enhanced by
      microbial fermentation of fibre, is still controversial. At the present time, our
      understanding of the effects of SCFA on human metabolism (in gut or systemically) is still
      limited. The investigators hypothesize that the ingested prebiotic inulin is fermented into
      SCFA and these SCFA have metabolic effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Fat oxidation, energy expenditure</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fat oxidation and energy expenditure are measured after inulin ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormones that influence substrate and energy metabolism</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Insulin, GLP-1, PYY, FIAF will be measured in plasma after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>LBP, TNF-Î±, IL-6, IL-1 will be measured in plasma after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating metabolites</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glucose, FFA, TG will be measured in plasma after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite VAS scoring</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analogue Scale for hunger and appetite are completed after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCFAs</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>SCFA content (acetate, butyrate and propionate, unlabeled and 13C-labeled) are measured after inulin ingestion in plasma, faeces, evtl muscle and adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath sampling 13CO2</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>In breath samples 13CO2 will be measured after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue and muscle gene/protein expression for inflammatory markers</measure>
    <time_frame>1 study day for each administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adipose tissue and muscle gene/protein expression for inflammatory markers will be measured after inulin ingestion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>13C inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C inulin combined with an inulin load are administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An inulin load is administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo is administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>13C inulin</intervention_name>
    <description>Oral 13C inulin</description>
    <arm_group_label>13C inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Oral inulin</description>
    <arm_group_label>13C inulin</arm_group_label>
    <arm_group_label>Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight, obese men

        Exclusion Criteria:

          -  athletes

          -  diabetes mellitus
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHC Dejong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHC Dejong, MD, PhD</last_name>
    <email>chc.dejong@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten van der Beek, MD</last_name>
      <email>k.vanderbeek@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Kees Dejong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsten van der Beek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
